Portal de Periódicos da CAPES

Immunity to SARS-CoV-2 up to 15 months after infection

2022; Cell Press; Volume: 25; Issue: 2 Linguagem: Inglês

10.1016/j.isci.2022.103743

2589-0042

Harold Marcotte, Antonio Piralla, Fanglei Zuo, Likun Du, Irene Cassaniti, Hui Wan, Makiko Kumagai‐Braesch, Juni Andréll, Elena Percivalle, Josè Camilla Sammartino, Yating Wang, Stelios Vlachiotis, Janine Attevall, Federica Bergami, Alessandro Ferrari, Marta Colaneri, Marco Vecchia, Margherita Sambo, Valentina Zuccaro, Erika Asperges, Raffaele Bruno, Tiberio Oggionni, Federica Meloni, Hassan Abolhassani, Federico Bertoglio, Maren Schubert, Luigi Calzolai, Luca Varani, Michael Hust, Yintong Xue, Lennart Hammarström, Fausto Baldanti, Qiang Pan‐Hammarström,

COVID-19 epidemiological studies

Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset. Following a peak at day 15-28 postinfection, the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. Compared to G614, plasma neutralizing titers were more than 8-fold lower against variants Beta, Gamma, and Delta. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months although a significant decrease in specific T cells, but not B cells, was observed between 6 and 15 months. Antiviral specific immunity, especially memory B cells in COVID-19 convalescent patients, is long-lasting, but some variants of concern may at least partially escape the neutralizing activity of plasma antibodies.